{"id":"NCT03745638","sponsor":"Incyte Corporation","briefTitle":"Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis","officialTitle":"A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-12-20","primaryCompletion":"2019-12-23","completion":"2020-12-01","firstPosted":"2018-11-19","resultsPosted":"2021-12-17","lastUpdate":"2023-09-28"},"enrollment":631,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Ruxolitinib Cream","otherNames":["INCB018424 Phosphate Cream"]},{"type":"DRUG","name":"Vehicle Cream","otherNames":[]}],"arms":[{"label":"VC Period: Vehicle Cream BID","type":"PLACEBO_COMPARATOR"},{"label":"VC Period: Ruxolitinib 0.75% Cream BID","type":"EXPERIMENTAL"},{"label":"VC Period: Ruxolitinib 1.5% Cream BID","type":"EXPERIMENTAL"},{"label":"LTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID","type":"EXPERIMENTAL"},{"label":"LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID","type":"EXPERIMENTAL"},{"label":"LTS Period: Ruxolitinib 0.75% Cream","type":"EXPERIMENTAL"},{"label":"LTS Period: Ruxolitinib 1.5% Cream","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the efficacy and safety of twice daily ruxolitinib cream in adolescents and adults with Atopic Dermatitis (AD).","primaryOutcome":{"measure":"Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8","timeFrame":"Baseline to Week 8","effectByArm":[{"arm":"VC Period: Vehicle Cream BID","deltaMin":15.1,"sd":null},{"arm":"VC Period: Ruxolitinib 0.75% Cream BID","deltaMin":50,"sd":null},{"arm":"VC Period: Ruxolitinib 1.5% Cream BID","deltaMin":53.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"},{"comp":"OG000 vs OG002","p":"< 0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":11},"locations":{"siteCount":79,"countries":["United States","Canada","France","Germany","Hungary","Italy","Poland"]},"refs":{"pmids":["39546129","39375281","38698175","36264430","33982267","33957195","33658996"],"seeAlso":["http://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217471&amp;parentIdentifier=INCB%2018424-303&amp;attachmentIdentifier=2e6d9279-95cb-4501-9243-8a7bec8f8514&amp;fileName=INCB18424-303_Plain_Language_Summary.pdf&amp;versionIdentifier=6d478571-324e-42b3-b2cc-0d7125ac1386"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":126},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Headache"]}}